RxDoctor Payments Data

Daphne Delgado Perez, MD

Pulmonary Disease · San Juan, PRNPI 1518926542

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,717 of the $9,566 with a category attached, or 70.2%. It is spread thinly across 25 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2023 at $3,032 and has fallen 71.2% since, to $873 in 2025.

$9,566in general payments, 2019–2025

Across 221 payments — averaging $43.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Merck$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • Mylan Specialty L.p.$395
  • Sanofi$374
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$2,71528%
  • Food & beverage$6,71770%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,566 in reported general payments places this provider in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$37,184
Medicare patients
118
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter321$215,484
OfevNintedanib Esylate11$144,543
Breo ElliptaFluticasone/Vilanterol339$139,431
FasenraBenralizumab16$91,656
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$28,441
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$28,130
Spiriva RespimatTiotropium Bromide50$26,555
SymbicortBudesonide/Formoterol Fumarate109$25,843
Wixela InhubFluticasone Propion/Salmeterol173$23,232
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate94$20,665
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$16,378
Azelastine Hcl595$15,269
Fluticasone Propionate651$11,765
Albuterol Sulfate HfaAlbuterol Sulfate280$11,596
Levalbuterol Tartrate HfaLevalbuterol Tartrate146$8,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$2,118$383,355720 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,713$187,47691 claims
AstraZenecaFasenra, Breztri Aerosphere, Symbicort$1,683$145,629168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →